MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, analysis-driven pharmaceutical-high quality cannabis extraction, distillation and derivative merchandise, these days announced it will provide cannabis concentrate merchandise in Denmark to two new health-related cannabis consumers beneath two separate white-label agreements. These consumers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ 1st provide agreements for the export of completed merchandise to Denmark.
Denmark granted sufferers legal access to cannabis-primarily based medicinal merchandise two years ago as portion of a 4-year pilot plan. The plan gives sufferers with protected item access and national wellness authorities with patient information that they can use to have an understanding of usage and efficacy. According to info complied by New Frontier Information and the Danish Ministry of Wellness, more than two,one hundred sufferers (mostly girls involving the ages of 42-64) received cannabis-primarily based medicinal merchandise from 429 prescribing medical doctors beneath this plan in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis industry for medicinal, wellness and adult use applications and these agreements represent yet another step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related industry with new and revolutionary health-related cannabis focused merchandise positions us for more development in Europe and adds to MediPharm Labs all-critical physique of know-how that we are leveraging to boost the design and style of our formulations for sufferers and customers everywhere.”
Beneath the agreements, 1 which has an initial two-year term and the second a 1-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil merchandise that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its consumers to start in October 2020, pending regulatory approval by applicable wellness authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured quite a few incredibly appealing domestic and international provide agreements with higher high quality partners, now like new consumers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new enterprise wins are a clear and critical validation of our selection to create a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Superior Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed merchandise to nations across the EU, like Denmark. The Organization entered into its 1st European white-label cannabis provide agreement that identical month with Therismos Restricted.
About Denmark’s Health-related Cannabis Industry
Denmark launched its 4-year health-related cannabis pilot plan on January 1st, 20181. Post-harvest Superior Manufacturing Processes (GMP) is expected for distribution of health-related cannabis merchandise in Denmarktwo.
By means of the plan, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 regions: discomfort triggered by many sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an comprehensive critique of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high quality cannabis oil and concentrates and sophisticated derivative merchandise using a Superior Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an professional, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 principal extraction lines for delivery of pure, trusted and precision -dosed cannabis merchandise for its consumers. By means of its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based merchandise to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure